RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Share Price Crosses Below 200 Day Moving Average – Should You Sell?

RegeneRx Biopharmaceuticals Inc. (OTCMKTS:RGRX – Get Free Report)’s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.02 and traded as low as $0.0007. RegeneRx Biopharmaceuticals shares last traded at $0.0007, with a volume of 158 shares changing hands.

RegeneRx Biopharmaceuticals Trading Down 99.6%

The business’s 50-day moving average price is $0.06 and its 200-day moving average price is $0.02.

About RegeneRx Biopharmaceuticals

(Get Free Report)

RegeneRx Biopharmaceuticals, Inc. is a biotechnology company focused on developing regenerative therapies based on thymosin beta 4, a naturally occurring peptide involved in tissue repair, cell migration and inflammation regulation. The company’s research has primarily targeted conditions affecting the eye and other tissues. RegeneRx’s lead product candidate, RGN-259, is a topical ophthalmic formulation of thymosin beta 4 under development for ocular surface disorders, including neurotrophic keratopathy and dry-eye-related conditions.

Featured Stories

Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.